Patients with ERα− primary tumours typically have a worse prognosis than patients with ERα+ tumours and thus it may be that within heterogeneous tumours, the more aggressive and invasive ERα− cells have increased likelihood of dissemination. This evidence concerns the gene ESR1 and neoplasm.